Table 2.
Estimated clinical sensitivity, specificity, and odds ratios for MammaPrint recurrence scores in women with lymph node-negative, estrogen receptor-positive or -negative Stage I or II breast cancer treated, and subsequent breast cancer outcome
| Publication | Study design | Total N (outcome)a | Metastasis by (yrs) | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | Odds ratio (95% CI) |
|---|---|---|---|---|---|---|
| Van’t Veer, et al.35 | Case-control, signature set | 78 (34) | 5 | 91 (76–98) | 59 (43–74) | 15 (3.6–72) |
| van de Vijver, et al.19 | Cohort | 67 (12) | 5 | 92 (62–99) | 58 (44–71) | 15 (1.8–86) |
| Buyse, et al.22 | Cohort, FDA submission | 302 (48) | 5 | 87 (75–95) | 41 (35–48) | 4.9 (1.9–13) |
| Summary | 5 | 8.8 (3.9–19) | ||||
| van de Vijver, et al.19 | Cohort | 151 (59) | 10 | 86 (75–94) | 57 (46–67) | 8.3 (3.3–21) |
| Buyse, et al.22 | Cohort, FDA submission | 302 (48) | 10 | 83 (72–91) | 42 (36–49) | 3.7 (1.8–7.9) |
| Summary | 10 | 5.2 (2.4–12) |
a
Total number in the study (number with primary outcome).